# Samphire Neuroscience

> Samphire Neuroscience is a London-based neurotechnology company building drug-free, hormone-free wearables for women's health. Its flagship product, Nettle, is a headband that uses transcranial direct current stimulation (tDCS) to gently modulate the brain regions tied to mood and pain, worn 20 minutes a day in the run-up to menstruation. Marketed as the first EU-cleared (CE-certified) neuromodulation device for women's health, Nettle targets PMS, PMDD, menstrual pain and related hormonal conditions. Founded in 2021 by neuroscientist Emilė Radytė and IP lawyer Alex Cook, the company has raised roughly $7.77M across pre-seed, seed and Series A rounds.

- **Founded:** 2021
- **Headquarters:** London, England, United Kingdom
- **Founders:** Emilė Radytė (Co-Founder & CEO), Alex Cook (Co-Founder & COO)
- **Team size:** ~20 employees
- **Products:** Nettle, Lutea, Companion app
- **Notable:** Nettle billed as the first EU-cleared (CE-certified) neuromodulation device for women's health, launched May 6, 2025., Clinical trial of ~50 participants showed an average 52% reduction in menstrual pain with the active device, with benefits continuing into the following cycle., 1st place at the 16th Healthcare Innovation World Cup.

## Products & services

- **Nettle** — A CE-certified, EU-cleared neuromodulation headband that applies transcranial direct current stimulation (tDCS) to the motor cortex (pain) and prefrontal cortex (mood). Worn 20 minutes daily, typically for the five days before menstruation, to reduce menstrual pain and stabilize mood. RRP around £359 / €409 / $449.
- **Lutea** — A general wellness product line extending Samphire's neurostimulation approach beyond the medical-device-regulated Nettle.
- **Companion app** — Cycle and symptom tracking app that pairs with the device and offers opportunities to participate in research.

## Achievements

- Nettle billed as the first EU-cleared (CE-certified) neuromodulation device for women's health, launched May 6, 2025.
- Clinical trial of ~50 participants showed an average 52% reduction in menstrual pain with the active device, with benefits continuing into the following cycle.
- 1st place at the 16th Healthcare Innovation World Cup.
- CEO Emilė Radytė selected as an NHS Innovation Accelerator Fellow.
- Sold out its initial production run twice during pre-launch.
- Raised approximately $7.77M total across pre-seed, seed and Series A.

## Latest updates

- **2025-06** — Closed a Series A round (~$4.9M) to scale Nettle and its women's health device pipeline.
- **2025-05** — Officially launched the CE-certified Nettle device across the UK and EU.
- **2024-02** — Raised $2.3M pre-seed led by SOSV and others to advance the Nettle wearable.

## Links

- Website: https://samphireneuro.com
- LinkedIn: http://www.linkedin.com/company/samphireneuro
- YouTube: https://www.youtube.com/@samphireneuro
- Instagram: https://www.instagram.com/samphireneuro/
- Facebook: https://www.facebook.com/samphireneuro/
- TikTok: https://www.tiktok.com/@samphireneuroscience

---

Profile page: https://yespress.io/samphire-neuroscience
Published by YesPress — https://yespress.io
Last updated: 2026-06-12